Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes

Details

• Alternative Title:
  Diabetes Care
• Personal Author:
  Li, Rui ; Zhang, Ping ; Barker, Lawrence E. ; Hoerger, Thomas J.
• Description:
  OBJECTIVE
  
  To assess the long-term cost-effectiveness of aspirin use among adults aged ≥40 years with newly diagnosed type 2 diabetes.
  
  RESEARCH DESIGN AND METHODS
  
  We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death.
  
  RESULTS
  
  Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios.
  
  CONCLUSIONS
  
  Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.
  
  
• Subjects:
  Adult Aged Aged, 80 And Over Aspirin Cost-Benefit Analysis Diabetes Mellitus, Type 2 Female Humans Hypoglycemic Agents Male Middle Aged Original Research Time Factors

  More +
• Source:
  Diabetes Care. 33(6):1193-1199.
• Document Type:
  Journal Article
• Volume:
  33
• Issue:
  6
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:dcbd66531db8bc365f989a95639c436a8fc120d9badb2cab0fbfc950652e5c52
• Download URL:
  https://stacks.cdc.gov/view/cdc/4395/cdc_4395_DS1.pdf
• File Type:
  [PDF - 159.21 KB ]